P/E ratio for Fate Therapeutics (FATE)

P/E ratio history for Fate Therapeutics from 2013 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Sarepta Therapeutics SRPT	-8.06	2,166.03%	🇺🇸 USA
Becton Dickinson BDX	41.0	-11,625.52%	🇺🇸 USA
PTC Therapeutics PTCT	-5.68	1,498.48%	🇺🇸 USA
Avidity Biosciences RNA	-9.42	2,549.95%	🇺🇸 USA
Neurocrine Biosciences NBIX	56.4	-15,972.50%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.